These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8796904)

  • 1. Intracellular immunization or immunotherapy for HIV infection?
    Featherstone C
    Mol Med Today; 1996 Jul; 2(7):271. PubMed ID: 8796904
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees.
    Boyer JD; Ugen KE; Chattergoon M; Wang B; Shah A; Agadjanyan M; Bagarazzi ML; Javadian A; Carrano R; Coney L; Williams WV; Weiner DB
    J Infect Dis; 1997 Dec; 176(6):1501-9. PubMed ID: 9395361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases.
    Rondon IJ; Marasco WA
    Annu Rev Microbiol; 1997; 51():257-83. PubMed ID: 9343351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroviral vectors for HIV immunotherapy.
    Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
    Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
    Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
    Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.
    Woffendin C; Ranga U; Yang Z; Xu L; Nabel GJ
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2889-94. PubMed ID: 8610137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains.
    Duan L; Zhang H; Oakes JW; Bagasra O; Pomerantz RJ
    Hum Gene Ther; 1994 Nov; 5(11):1315-24. PubMed ID: 7893803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
    Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
    Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments.
    Duan L; Zhu M; Bagasra O; Pomerantz RJ
    Hum Gene Ther; 1995 Dec; 6(12):1561-73. PubMed ID: 8664381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments.
    Ho WZ; Lai JP; Bouhamdan M; Duan L; Pomerantz RJ; Starr SE
    AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1573-80. PubMed ID: 9840290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
    Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
    Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transduction of CD34+ cells from the bone marrow of HIV-1-infected children: comparative marking by an RRE decoy gene and a neutral gene.
    Hum Gene Ther; 2000 Jul; 11(11):1577-90. PubMed ID: 10945771
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and titer of anti-rev antibody in HIV infection.
    Dairaku M; Tsuchie H; Ushijima H; Aoki I; Okuda K; Honda M; Ikegami N; Hachimori K; Matsuda J; Kitamura T
    AIDS; 1989 Nov; 3(11):765-6. PubMed ID: 2515884
    [No Abstract]   [Full Text] [Related]  

  • 19. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
    Tubiana R; Gomard E; Fleury H; Gougeon ML; Mouthon B; Picolet H; Katlama C
    AIDS; 1997 May; 11(6):819-20. PubMed ID: 9143616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.